Anemia And Other Blood Disorder Drugs Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The Business Research Company's Anemia And Other Blood Disorder Drugs Global Market Report 2024 identifies the increasing prevalence of anemia among the global populationas the major driver for the anemia and other blood disorder drugs market's growth in the forecast period.Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the anemia and other blood disorder drugs market.

The anemia and other blood disorder drugs market size has grown strongly in recent years. It will grow from $11.13 billion in 2023 to $11.91 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, aging population, pharmaceutical innovation, patient awareness.

The anemia and other blood disorder drugs market size is expected to see strong growth in the next few years. It will grow to $15.49 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emerging markets, global demographics, economic factors. Major trends in the forecast period include research and development, technological advances, biologics and targeted therapies, gene therapies, telemedicine and remote monitoring, orphan drug designations, mergers and acquisitions.

Download Free Sample Of Anemia And Other Blood Disorder Drugs Market Report - https://www.thebusinessresearchcompany.com/sample_request?id=2465&type=smp

Major competitors in the anemia and other blood disorder drugs market are Amgen Inc., GlaxoSmithKline PLC, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc.

A key trend in the anemia and other blood disorder drugs market includes technological advancement. Major companies operating in the anemia and other blood disorder drugs market are increasing their focus on introducing novel medications to gain a competitive edge in the market. Novel medications refer to pharmaceutical products that represent a significant advancement or a new approach to the treatment of medical conditions or diseases. For instance, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis-stimulating agent (ESA) in MDS-related anemia based on interim results from pivotal Phase 3 COMMANDS. The approval was supported by data from the COMMANDS study, a global phase 3 trial in which nearly twice as many patients treated with Reblozyl achieved transfusion independence of at least 12 weeks and a concurrent hemoglobin increase compared to Epoetin alfa.

Read More On The Global Anemia And Other Blood Disorder Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

The anemia and other blood disorder drugs market is segmented -
• By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
• By Route of Administration: Oral, Injectable
• By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the anemia and other blood disorder drugs market.

The Business Research Company's "Global Anemia And Other Blood Disorder Drugs Market Report 2024" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The Anemia And Other Blood Disorder Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2465

The Table Of Content For The Anemia And Other Blood Disorder Drugs Market Include:
1. Executive Summary
2. Anemia And Other Blood Disorder Drugs Market Characteristics
3. Anemia And Other Blood Disorder Drugs Market Trends And Strategies
4. Anemia And Other Blood Disorder Drugs Market - Macro Economic Scenario
5. Global Anemia And Other Blood Disorder Drugs Market Size and Growth
……
31. Global Anemia And Other Blood Disorder Drugs Market Competitive Benchmarking
32. Global Anemia And Other Blood Disorder Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Anemia And Other Blood Disorder Drugs Market
34. Anemia And Other Blood Disorder Drugs Market Future Outlook and Potential Analysis
35. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.